Figure and legend list:
Figure 1. CMV DNA plasma titers by PCR (y-axis) and therapeutic
interventions throughout HSCT course over time (x-axis). Exams under
anesthesia (EUA) are indicated as well as CMVR status based on
qualitative CMV DNAemia results in aqueous humor of right (OD) and left
eye (OS), respectively.
Figure 2. A) MRI Brain on day of CMVR recurrence (Day +158
post-HCT) showing right optic nerve enhancement. B) Composite of
Fluorescein Angiography (FA), Color Fundus Photography (CFP), and
Optical Coherence Tomography B-scans (OCT) of right (OD) and left eye
(OS), respectively. Grey panels indicate no imaging from the patient was
collected on that date. Panels A-F: imaging from initial exam under
anesthesia (Day +158 post-HCT). Panels G-J: imaging from time of
quiescence prior to initiation of tocilizumab (Day +226 post-HCT).
Panels K-N: imaging from 6 months after final tocilizumab infusion and 2
rounds of VST therapy (Day +517 post-HCT). Panels S-X: imaging from most
recent EUA with quiescence and improvement after 3 rounds of VST therapy
(Day +694 post-HCT). Yellow arrows show progressive decrease in optic
disc edema and retinal vasculitis (represented by decreased
hyperfluorescence in angiogram) and red arrows show progressive decrease
in macular edema (represented by decreased retinal thickening on OCT) in
both eyes.